HK1040920B - 缓释药物组合物和释放药学活性试剂的方法 - Google Patents

缓释药物组合物和释放药学活性试剂的方法 Download PDF

Info

Publication number
HK1040920B
HK1040920B HK02102698.9A HK02102698A HK1040920B HK 1040920 B HK1040920 B HK 1040920B HK 02102698 A HK02102698 A HK 02102698A HK 1040920 B HK1040920 B HK 1040920B
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
composition
average molecular
number average
active agent
Prior art date
Application number
HK02102698.9A
Other languages
English (en)
Chinese (zh)
Other versions
HK1040920A1 (en
Inventor
R‧沙赫
A‧P‧帕特尔
R‧T‧萨德瑞
A‧P‧帕特爾
R‧T‧薩德瑞
Original Assignee
诺瓦提斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22627919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1040920(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 诺瓦提斯公司 filed Critical 诺瓦提斯公司
Publication of HK1040920A1 publication Critical patent/HK1040920A1/xx
Publication of HK1040920B publication Critical patent/HK1040920B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK02102698.9A 1998-10-14 1999-10-12 缓释药物组合物和释放药学活性试剂的方法 HK1040920B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17249198A 1998-10-14 1998-10-14
US09/172,491 1998-10-14
PCT/EP1999/007627 WO2000021525A2 (en) 1998-10-14 1999-10-12 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Publications (2)

Publication Number Publication Date
HK1040920A1 HK1040920A1 (en) 2002-06-28
HK1040920B true HK1040920B (zh) 2005-07-29

Family

ID=22627919

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102698.9A HK1040920B (zh) 1998-10-14 1999-10-12 缓释药物组合物和释放药学活性试剂的方法

Country Status (30)

Country Link
EP (1) EP1121116B1 (enExample)
JP (2) JP2002527388A (enExample)
KR (1) KR100517090B1 (enExample)
CN (1) CN1196481C (enExample)
AR (2) AR020780A1 (enExample)
AT (1) ATE382345T1 (enExample)
AU (1) AU765475B2 (enExample)
BR (1) BR9911648A (enExample)
CA (1) CA2346868C (enExample)
CO (1) CO5140079A1 (enExample)
CY (1) CY1107874T1 (enExample)
DE (1) DE69937891T2 (enExample)
DK (1) DK1121116T3 (enExample)
ES (1) ES2297936T3 (enExample)
HK (1) HK1040920B (enExample)
HU (1) HUP0104268A3 (enExample)
ID (1) ID29350A (enExample)
IL (2) IL142375A0 (enExample)
MY (1) MY121105A (enExample)
NO (1) NO327285B1 (enExample)
NZ (1) NZ511010A (enExample)
PE (1) PE20001110A1 (enExample)
PL (1) PL198850B1 (enExample)
PT (1) PT1121116E (enExample)
RU (1) RU2259826C2 (enExample)
SK (2) SK286596B6 (enExample)
TR (1) TR200101088T2 (enExample)
TW (1) TW577738B (enExample)
WO (1) WO2000021525A2 (enExample)
ZA (1) ZA200103001B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
ATE418979T2 (de) 2000-06-09 2009-01-15 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
DK1345595T3 (da) * 2000-09-29 2007-09-10 Solvay Pharm Bv Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20060039974A1 (en) * 2002-09-11 2006-02-23 Takeda Pharmaceutical Company Limited Sustained release preparation
JP2007523664A (ja) * 2003-04-23 2007-08-23 フェリング ベスローテン フェンノートシャップ 医薬組成物用サシェ
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
EP1940391A4 (en) * 2005-08-05 2010-01-20 Orbus Pharma Inc STABILIZED PHARMACEUTICAL COMPOSITIONS WITH EXTENDED RELEASE WITH AN HMG COA REDUCTASE INHIBITOR
BRPI0708191A2 (pt) * 2006-02-24 2012-05-29 Teva Pharma " composições farmacêuticas de fluvastatina sódica "
RU2342144C1 (ru) * 2007-04-05 2008-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав, обладающий противосудорожным и психотропным действием
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
BR112015016322A8 (pt) * 2013-01-09 2018-01-23 Edgemont Pharmaceuticals Llc formulações de liberação controlada de lorazepam
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
EP3720434A4 (en) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. NON-RACEMIC MIXTURES AND THEIR USES
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
MX2021014774A (es) 2019-06-04 2022-02-03 Sunovion Pharmaceuticals Inc Formulaciones de liberacion modificada y usos de las mismas.
TWI869410B (zh) * 2019-06-10 2025-01-11 愛爾蘭商龐賽德萊昂健康公司 α－酮戊二酸鹽之持續釋放組合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
EP0465096A1 (en) * 1990-06-26 1992-01-08 Merck & Co. Inc. Plasma cholesterol level lowering composition
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
AU706628B2 (en) * 1995-07-03 1999-06-17 Sankyo Company Limited Treatment of arteriosclerosis and xanthoma
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
SI0814782T1 (en) * 1995-12-22 2003-04-30 Kowa Company, Ltd. Pharmaceutical composition stabilized with a basic agent
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
ATE382345T1 (de) 2008-01-15
CY1107874T1 (el) 2013-06-19
RU2259826C2 (ru) 2005-09-10
AR069281A2 (es) 2010-01-13
ES2297936T3 (es) 2008-05-01
CN1196481C (zh) 2005-04-13
NO20011695D0 (no) 2001-04-04
AU765475B2 (en) 2003-09-18
PL198850B1 (pl) 2008-07-31
EP1121116A2 (en) 2001-08-08
JP2002527388A (ja) 2002-08-27
CN1328454A (zh) 2001-12-26
MY121105A (en) 2005-12-30
IL142375A (en) 2012-01-31
WO2000021525A3 (en) 2000-08-10
NZ511010A (en) 2003-10-31
IL142375A0 (en) 2002-03-10
DE69937891T2 (de) 2008-12-11
EP1121116B1 (en) 2008-01-02
HUP0104268A3 (en) 2002-06-28
NO20011695L (no) 2001-05-30
CA2346868C (en) 2008-09-09
AU6090999A (en) 2000-05-01
CO5140079A1 (es) 2002-03-22
BR9911648A (pt) 2001-03-20
DE69937891D1 (de) 2008-02-14
TW577738B (en) 2004-03-01
KR100517090B1 (ko) 2005-09-27
NO327285B1 (no) 2009-06-02
WO2000021525A2 (en) 2000-04-20
PL348109A1 (en) 2002-05-06
TR200101088T2 (tr) 2001-10-22
AR020780A1 (es) 2002-05-29
HK1040920A1 (en) 2002-06-28
JP4938383B2 (ja) 2012-05-23
HUP0104268A2 (hu) 2002-04-29
JP2006298945A (ja) 2006-11-02
DK1121116T3 (da) 2008-05-13
PT1121116E (pt) 2008-03-12
KR20010080156A (ko) 2001-08-22
SK286595B6 (sk) 2009-01-07
CA2346868A1 (en) 2000-04-20
ID29350A (id) 2001-08-23
SK286596B6 (sk) 2009-01-07
PE20001110A1 (es) 2000-11-01
ZA200103001B (en) 2002-07-11
SK5092001A3 (en) 2001-09-11

Similar Documents

Publication Publication Date Title
CN1196481C (zh) 缓释药物组合物和释放药学活性试剂的方法
US20100311802A1 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
JP2519296B2 (ja) イブプロフェン除放性錠剤及びその製造方法
JP5788547B2 (ja) コア層と１又は複数のバリヤー層を含む徐放性経口投与用配合剤
US20050192259A1 (en) Aldosterone antagonist compositions for release during aldosterone acrophase
CN1607947A (zh) 包含3－(3－二甲基氨基－1－乙基－2－甲基－丙基)苯酚并能提供活性成分的延迟释放的药物
US20050025825A1 (en) Tranexamic acid formulations with reduced adverse effects
CN1134665A (zh) 含有血管紧张素转化酶抑制剂雷米普利和二氢吡啶类化合物的新药物组合物
WO1998047491A2 (en) Controlled release formulations using intelligent polymers
JP2007532620A (ja) 両親媒性デンプンを含む医薬組成物
CN1525855A (zh) 治疗与预防心脏病与循环系统疾病的日服一次疗法用口服的控释医药组合物
CN1553799A (zh) 具有延长的活性成分释放的剂型
CN1946426A (zh) 用于口服施用HMG－CoA还原酶抑制剂的持续释放制剂和其制备方法
CN1988884A (zh) 控制释放基质的药物剂型组成
CN102112115A (zh) 雷米普利调节释放组合物及其应用
CN1867326A (zh) 加巴喷丁的缓释口服片剂及其制备方法
MXPA01003731A (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
CN1217668C (zh) 红霉素衍生物的缓释制剂
WO2006010995A1 (en) Controlled release compositions of divalproex sodium

Legal Events

Date Code Title Description
PE Patent expired